On January 16, ZYLOTB Medical Technology Co., Ltd. (hereinafter referred to as "ZYLOXTB (02190)") announced it has signed an agreement with Germany's Optimed Medizinische Instrumente GmbH, a medical technology company specializing in minimally invasive vascular and urological interventions. The agreement involves a phased acquisition of Optimed's equity, granting ZYLOXTB an option to acquire all remaining equity and corresponding interests in the future. This acquisition marks a significant milestone in the company's global development strategy. By integrating Optimed's established R&D, manufacturing, and commercialization platform in Europe, ZYLOXTB will further expand its presence in European and global markets, accelerating the international promotion and deployment of its innovative products. Furthermore, leveraging the synergistic effects between its production bases in China and Germany, the company will continuously enhance its global operational and delivery capabilities, bringing high-quality and affordable innovative products and solutions to a greater number of patients.
The transaction will robustly support the in-depth implementation of ZYLOXTB's internationalization strategy, accelerating its expansion into Europe and other core overseas markets, and further driving the commercial deployment of innovative products in more countries and regions. Following the completion of the deal, ZYLOXTB and Optimed will comprehensively integrate their commercial platforms, including existing sales and marketing networks, academic promotion teams, and customer service systems, to build a unified, synergistic, and efficient global commercial operation system. This will enable the delivery of high-quality, affordable medical solutions to more patients and physicians. Additionally, ZYLOXTB will leverage Optimed's academic network in Europe to expedite international clinical trials, post-market surveillance studies, and commercialization for related products.
Optimed is a German medical technology enterprise focused on the R&D, production, and global sales of minimally invasive vascular and urological intervention devices. Founded in 1996 and headquartered in Germany, the company's current sales and service network spans more than 70 countries, maintaining long-term, close collaboration with European clinicians and academic opinion leaders. With a production facility in Germany, Optimed adheres to stringent quality standards, delivering excellent products and services to patients worldwide through leading manufacturing processes and efficient supply chain management. In the field of peripheral venous therapy, several of Optimed's venous stent products enjoy broad market recognition and a strong brand reputation. The efficacy of its iliac vein stent, sinus-Venous, has been fully validated in the STEVECO clinical trial. STEVECO is the first prospective, randomized, multicenter study in the field of chronic deep venous obstruction, with results showing that patients treated with the product experienced significant improvements in quality of life and reduction in disease severity compared to those receiving conservative treatment.
ZYLOXTB stated that this transaction will also significantly enhance the company's R&D and manufacturing capabilities in overseas markets. Utilizing Optimed's local production base in Germany, the company will further expand its global production capacity, enabling more stable and efficient service for customers in Europe and other key international markets. Concurrently, the two entities will achieve synergies in production and operations, continuously improving product quality and operational efficiency. Moreover, ZYLOXTB will capitalize on the strengths of its efficient R&D system, integrating Optimed's R&D resources and clinical network across Europe and globally to bring clinically valuable innovative products to the international market more rapidly. Through deep integration across R&D, manufacturing, and commercialization, ZYLOXTB will further construct a globally-oriented operational platform, establishing a stable pipeline for international product output and delivering more safe, reliable, and technologically advanced innovative medical solutions to physicians and patients worldwide.
Dr. Zhao Zhong, Chairman and CEO of ZYLOXTB, stated, "This acquisition is a major milestone in ZYLOXTB's international strategy. By synergizing with Optimed's R&D, manufacturing, and commercial platform, the company will solidify its footprint in Europe and global markets, accelerating the pace of our international strategic development. We warmly welcome Optimed to the ZYLOXTB family. Moving forward, both parties will fully leverage their complementary strengths in product portfolios, production operations, and commercial platforms to build an integrated operational platform spanning China and Europe. This will bring more innovative vascular intervention solutions to global doctors and patients and propel the company into its next phase of growth."
Rüdiger Hausherr, CEO of Optimed, said, "For nearly three decades, Optimed has worked closely with physicians, building a trusted brand foundation in the vascular and urological intervention fields. As the global healthcare market environment continuously evolves, Optimed also needs to build upon its existing foundation and rely on an international platform with greater comprehensive strength to better serve global customers and achieve long-term development. Over the past few months, we have reached a high degree of strategic consensus with ZYLOXTB regarding future development. ZYLOXTB's strengths in product R&D and manufacturing are highly complementary to Optimed's international commercial platform, which will open new growth opportunities for the company and deliver more valuable innovative solutions to physicians and patients worldwide."
